Report top-line data from the global Phase 2/3 study of opaganib
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 17 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“top-line data from global Phase 2/3 study in hospitalized patients with opaganib, RedHill’s second COVID-19 candidate, is expected Q2/2021”
What we found
Evidence strength A What the grades mean
Top-line data were reported in September 2021, after the Q2 2021 deadline. A July 2021 filing said results were still expected in the coming weeks.
-
A RedHill Biopharma Ltd. 6-K filed 2021-07-19
“all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640)1 in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.” ✓ confirmed on the page
-
A RedHill Biopharma Ltd. 20-F filed 2022-03-17
“In September 2021, we reported that preliminary top-line data from the opaganib (ABC294640) global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia showed that the study did not meet its primary endpoint.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- top-line data from global Phase 2/3 study of opaganib
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you RedHill Biopharma Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-RDHL-023997 · Corrections policy